Govt clears GlaxoSmithKline’s Rs. 6,400 cr FDI proposal

February 20, 2014 12:43 pm | Updated May 18, 2016 09:40 am IST - New Delhi

File photo shows the GlaxoSmithKline offices in London. The CCEA on Thursday cleared the FDI proposal of GlaxoSmithKline which would result in FDI of approximately Rs. 6,390 crore.

File photo shows the GlaxoSmithKline offices in London. The CCEA on Thursday cleared the FDI proposal of GlaxoSmithKline which would result in FDI of approximately Rs. 6,390 crore.

The government on Thursday cleared Rs. 6,400 crore FDI proposal of global healthcare company GlaxoSmithKline to acquire additional 24.33 per cent stake in its India arm.

The Cabinet Committee on Economic Affairs (CCEA) has approved the proposal of GlaxoSmithKline Pte Limited, Singapore for acquisition of 24.33 percent shares in existing Indian subsidiary company of GSK Group.

The said acquisition “would be done by way of a voluntary open offer under SEBI (SAST Regulations) in the pharmaceutical sector,” an official statement said on Thursday.

“The approval would result in foreign investment of approximately Rs. 6,390 crore in the country,” the statement added.

GlaxoSmithKline Pharmaceuticals is already majority owned and controlled by the GSK Group.

After the purchase, holding of the promoter group firm in the Indian subsidiary will go up to 75 per cent from the current level of 50.67 per cent.

GSK Pharma makes, distributes and trades in a variety of drugs. Its portfolio include prescription medicines and vaccines across areas such as anti-infectives, dermatology, and gynaecology.

The company employs more than 5,000 people and generated more than Rs. 2,600 crore turnover during the financial year ended December 31, 2012.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.